Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.

Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.

View in: PubMed

collapse authors with profiles